Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 5/2012

01.10.2012 | Research Article

Cost effectiveness of three drugs for the treatment of S. aureus infections in Nigeria

verfasst von: Ismail Ayinla Suleiman, Babajide Solomon Bamiro, Fola Tayo

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 5/2012

Einloggen, um Zugang zu erhalten

Abstract

Background Resistance of microorganisms to existing antimicrobial agents threatens the effective utilization of available resources in sub-Saharan Africa. Cost-effective utilization of antibacterial agents is essential in effective health care delivery in Nigeria. Objectives To determine the most cost effective antibacterial agent in the treatment of S. aureus infections in Lagos metropolis. Setting The study was carried out in a teaching hospital, a specialist hospital, a referral center and two private hospitals. Methods Cost effectiveness analysis of ciprofloxacin, cefuroxime and gentamicin identified to be most effective agent against 463 clinical isolates of S. aureus obtained from the five hospitals was carried out on the basis of societal, health care and third party perspectives using ‘decision table” as an analytical model. Criteria considered in the model included degree of efficacy of the agents, adherence tendencies and tolerability. Both direct (cost of drugs, diagnosis/monitoring, personnel and transportation) and indirect (loss of productivity) costs were evaluated. Main outcome measures These include economic outcome as total therapy cost, clinical outcomes as extent of antibacterial effectiveness obtained from degree of antibacterial efficacy, a proxy measurement of cure rates, and adherence tendency. Humanistic outcome was also measured as tolerability prorated from literature reported degree of adverse drug reactions events, risk of infection and pains from drug administration. Results Ciprofloxacin tablet is a dominant option and much more cost-effective than either cefuroxime or gentamicin in the treatment of S. aureus in Lagos. Regardless of the perspective of analysis, ciprofloxacin has the least cost effectiveness ratio of NGN4214.66 ($28.09), NGN2392.63 ($16.00) and NGN2048.66 ($13.65) from societal, health care and third party payer perspectives, respectively. Sensitivity analysis by increasing the effectiveness index of gentamicin injection-the least cost effective option to the value for the most cost effective option did not change the results. Conclusion Ciprofloxacin should be used as first-line-treatment of S aureus in Lagos as it will lead to significant cost savings in the treatment of S. aureus infections.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Okeke IN, Lamikanra A, Edelman R. Socioeconomic and behavioural factors leading to acquired bacterial resistance to antibiotics in developing countries. Emerg Infect Dis. 1999;5:1.CrossRef Okeke IN, Lamikanra A, Edelman R. Socioeconomic and behavioural factors leading to acquired bacterial resistance to antibiotics in developing countries. Emerg Infect Dis. 1999;5:1.CrossRef
2.
Zurück zum Zitat Franco BE, Martínez MA, Rodríguez MAS, Wertheimer AI. The determinants of the antibiotic resistance process. Infect Drug Resist. 2009;2:1–11.PubMed Franco BE, Martínez MA, Rodríguez MAS, Wertheimer AI. The determinants of the antibiotic resistance process. Infect Drug Resist. 2009;2:1–11.PubMed
3.
Zurück zum Zitat World Health Organisation. Global strategy for containment of anti-microbial resistance. Geneva, Switzerland: World Health Organisation, 2001; WHO/CDS/CSR/DRS/2001.2. World Health Organisation. Global strategy for containment of anti-microbial resistance. Geneva, Switzerland: World Health Organisation, 2001; WHO/CDS/CSR/DRS/2001.2.
4.
Zurück zum Zitat Adesida S, Bockens, H, Babajide, B, Kehinde, A, Snijders, S, van Leeuwen W. et al. A major epidemic clones of Staphylococcus aureus in Nigeria. Microb Drug Resist. 2005 Summer;11(2):115–121. Adesida S, Bockens, H, Babajide, B, Kehinde, A, Snijders, S, van Leeuwen W. et al. A major epidemic clones of Staphylococcus aureus in Nigeria. Microb Drug Resist. 2005 Summer;11(2):115–121.
5.
Zurück zum Zitat Suleiman IA, Tayo F. Comparative costs of antibacterial usage in sexully transmitted infections in a Nigerian teaching hospital. Trop J Pharm Res. 2010;9(6):549–55. Suleiman IA, Tayo F. Comparative costs of antibacterial usage in sexully transmitted infections in a Nigerian teaching hospital. Trop J Pharm Res. 2010;9(6):549–55.
7.
Zurück zum Zitat Webler JT, Courvalin P. An empty quiver: antimicrobial drugs and resistance. Emerg Infect Dis. 2005;11(6):791–3.CrossRef Webler JT, Courvalin P. An empty quiver: antimicrobial drugs and resistance. Emerg Infect Dis. 2005;11(6):791–3.CrossRef
8.
Zurück zum Zitat Drummond MF. Method for the Economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; Preview 2005. ISBN: 0-19-852945-7. Drummond MF. Method for the Economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; Preview 2005. ISBN: 0-19-852945-7.
10.
Zurück zum Zitat Murray PR, Baron FJ, Pfaller MA, Tenover FC, Yolken RH. Manual of clinical microbiology. 7th ed. Washington: ASM Press; 1999. ISBN: 1555812554, 9781555812553. Murray PR, Baron FJ, Pfaller MA, Tenover FC, Yolken RH. Manual of clinical microbiology. 7th ed. Washington: ASM Press; 1999. ISBN: 1555812554, 9781555812553.
11.
Zurück zum Zitat National Committee for Clinical Laboratory Standard Institute (NCCLS). Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A7 NCCLS, Wayne, PA. The Committee 2001. National Committee for Clinical Laboratory Standard Institute (NCCLS). Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A7 NCCLS, Wayne, PA. The Committee 2001.
12.
Zurück zum Zitat Clinical and Laboratory Standard Institute (CLSI). Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A10, Wayne, PA: Clinical and Laboratory Standards Institute; 2009. ISBN: 1562385887, 9781562385880. Clinical and Laboratory Standard Institute (CLSI). Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A10, Wayne, PA: Clinical and Laboratory Standards Institute; 2009. ISBN: 1562385887, 9781562385880.
13.
Zurück zum Zitat Cano SB, Fujita NK. Formulary evaluation of third generation cephalosporins using decision analysis. Am J of Hosp Pharm. 1988;45:566–9. Cano SB, Fujita NK. Formulary evaluation of third generation cephalosporins using decision analysis. Am J of Hosp Pharm. 1988;45:566–9.
14.
Zurück zum Zitat Suleiman IA, Tayo F. Pharmacoeconomic evaluation of antimicrobial agents in the treatment of sexually transmitted diseases in Lagos University Teaching Hospital. West Afr J Pharm. 2004;18(1):42–52. Suleiman IA, Tayo F. Pharmacoeconomic evaluation of antimicrobial agents in the treatment of sexually transmitted diseases in Lagos University Teaching Hospital. West Afr J Pharm. 2004;18(1):42–52.
15.
Zurück zum Zitat Neithimer AI. The defined daily dose system (DDD) for drug utilization review. Hosp Pharm. 1986;21:233–41. Neithimer AI. The defined daily dose system (DDD) for drug utilization review. Hosp Pharm. 1986;21:233–41.
16.
Zurück zum Zitat WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2012. Oslo; 2011. ISSN: 1726-4898, ISBN: 978-82-8082-477-6. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2012. Oslo; 2011. ISSN: 1726-4898, ISBN: 978-82-8082-477-6.
17.
Zurück zum Zitat Joel E, Sagel BA. Cost of illness studies—a primer. North Carolina: RTI International RTI-UNC Centre for Excellence in Health promotion Economics; 2006. Joel E, Sagel BA. Cost of illness studies—a primer. North Carolina: RTI International RTI-UNC Centre for Excellence in Health promotion Economics; 2006.
18.
Zurück zum Zitat Hodgson TA, Meiners MR. Cost of illness methodology: a guide to current practices and procedures. Milbank Mem Fund Q. 1982;60(3):429–62.CrossRef Hodgson TA, Meiners MR. Cost of illness methodology: a guide to current practices and procedures. Milbank Mem Fund Q. 1982;60(3):429–62.CrossRef
19.
Zurück zum Zitat Taylor O, Chukwani CM, Eniojukan JF, Fajemirokun O. Socioeconomic evaluation of parenteral antibacterial therapy in Lagos University Teaching Hospital. Results of a retrospective survey. West Afr J Pharm. 1997;11(2):78–86. Taylor O, Chukwani CM, Eniojukan JF, Fajemirokun O. Socioeconomic evaluation of parenteral antibacterial therapy in Lagos University Teaching Hospital. Results of a retrospective survey. West Afr J Pharm. 1997;11(2):78–86.
20.
Zurück zum Zitat Mandell LA. Improved safety profile of newer fluoroquinolone. In: Ronald AR, Low DE, editors. Fluoroquinolone Antibiotics. Basel: Birkhauser; 2003. pp. 73–86. ISBN: 3-7643-6591-9. Mandell LA. Improved safety profile of newer fluoroquinolone. In: Ronald AR, Low DE, editors. Fluoroquinolone Antibiotics. Basel: Birkhauser; 2003. pp. 73–86. ISBN: 3-7643-6591-9.
21.
Zurück zum Zitat American Hospital Formulary Services Drug information® AHFS. 1999 edition. Bethesda, MD, USA: American Society of Health-System Pharmacists. American Society of Health-System Pharmacists Inc.1999; pp. 123–226. ISBN: 978-1-58528-247-0. American Hospital Formulary Services Drug information® AHFS. 1999 edition. Bethesda, MD, USA: American Society of Health-System Pharmacists. American Society of Health-System Pharmacists Inc.1999; pp. 123–226. ISBN: 978-1-58528-247-0.
22.
Zurück zum Zitat Bank NU, Kammer RB. Heamatologic complications associated with β-lactam antibiotics. Rev Infect Dis. 1983;5:S380–98.CrossRef Bank NU, Kammer RB. Heamatologic complications associated with β-lactam antibiotics. Rev Infect Dis. 1983;5:S380–98.CrossRef
23.
Zurück zum Zitat Kahlmeter G, Dahlager JI. Aminoglycoside toxicity—a review of clinical studies published between 1975 and 1982. J Antimicrob Chemother. 1984;13(Suppl A):9–22.PubMed Kahlmeter G, Dahlager JI. Aminoglycoside toxicity—a review of clinical studies published between 1975 and 1982. J Antimicrob Chemother. 1984;13(Suppl A):9–22.PubMed
24.
Zurück zum Zitat Ghebremedhin B, Olugbosi MO, Raji AM, Layer F, Bakare RA, König B, König W. Emergence of a community-associated methicillin-resistant Staphylococcus aureus strain with a unique resistance profile in Southwest Nigeria. J Clin Microbiol. 2009;47(9):2975–80. (Epub 2009 Jul 1).PubMedCrossRef Ghebremedhin B, Olugbosi MO, Raji AM, Layer F, Bakare RA, König B, König W. Emergence of a community-associated methicillin-resistant Staphylococcus aureus strain with a unique resistance profile in Southwest Nigeria. J Clin Microbiol. 2009;47(9):2975–80. (Epub 2009 Jul 1).PubMedCrossRef
25.
Zurück zum Zitat Terry Alli OA, Ogbolu DO, Akorede E, Onemu OM, Okanlawon BM. Distribution of mecA gene amongst Staphylococcus aureus isolates from South western Nigeria. Afr J Biomed Res. 2011;14(1):9–16. Terry Alli OA, Ogbolu DO, Akorede E, Onemu OM, Okanlawon BM. Distribution of mecA gene amongst Staphylococcus aureus isolates from South western Nigeria. Afr J Biomed Res. 2011;14(1):9–16.
26.
Zurück zum Zitat Pablos AI, Escober L, Albinana S, et al. Evaluation of an antibiotic intravenous to oral sequential therapy programme. Pharmacoepidemiol Drug Saf. 2005;14(1):53–9.PubMedCrossRef Pablos AI, Escober L, Albinana S, et al. Evaluation of an antibiotic intravenous to oral sequential therapy programme. Pharmacoepidemiol Drug Saf. 2005;14(1):53–9.PubMedCrossRef
27.
Zurück zum Zitat Bounthavong M, Zargarzadeh A, Hsu DI, Vanness DJ. Cost-effectiveness analysis of linezolid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus: complicated skin and skin structure infection using Bayesian methods for evidence synthesis. Value Health. 2011;14(5):631–9.PubMedCrossRef Bounthavong M, Zargarzadeh A, Hsu DI, Vanness DJ. Cost-effectiveness analysis of linezolid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus: complicated skin and skin structure infection using Bayesian methods for evidence synthesis. Value Health. 2011;14(5):631–9.PubMedCrossRef
Metadaten
Titel
Cost effectiveness of three drugs for the treatment of S. aureus infections in Nigeria
verfasst von
Ismail Ayinla Suleiman
Babajide Solomon Bamiro
Fola Tayo
Publikationsdatum
01.10.2012
Verlag
Springer Netherlands
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 5/2012
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-012-9671-x

Weitere Artikel der Ausgabe 5/2012

International Journal of Clinical Pharmacy 5/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.